BUY Mankind Pharma Limited — Motilal Oswal
byMotilal OswalHorizon: NA (inferred 1 year)31 Jul 2026via Moneycontrol Broker Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·23 Oct · yesterday
Mankind Pharma to acquire a majority stake in Armed Cell Therapeutics to enter the CAR-T therapy market.
BSE · Company Update·15 Oct · 1w ago
Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.
NSE · Acquisition·15 Oct · 1w ago
Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.
BSE · Company Update·15 Oct · 1w ago
Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.
NSE · Outcome of Board Meeting·15 Oct · 1w ago
Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation
NewsGoogle News·28 Sept · 4w ago
Mankind Pharma's subsidiary Bharat Serums and Vaccines sees auditor resignation amid liquidation
NewsGoogle News·28 Sept · 4w ago
1 other SEBI-registered advisor has an active long-term SELL call on this stock
Advisor consensus · same horizon·31 Jul · 3mo ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Mankind Pharma
- BUY — Rajesh Satpute7 Oct 2026 · Next day · target ₹2,550 · SL hit
- BUY — Swati Hotkar, Nirmal Bang Securities7 Oct 2026 · Same day · target ₹2,580 · Expired
- SELL — Macquarie7 Oct 2026 · ~1 year · target ₹2,200 · Target hit
- BUY — Vishvesh Chauhan, ChaseAlpha30 Sept 2026 · ~2 weeks · target ₹2,640 · SL hit
- BUY — Raja Venkatraman30 Sept 2026 · ~3 months · target ₹2,800 · SL hit
More from Motilal Oswal
- BUY Colgate Palmolive (India)22 Oct 2026 · ~1 year · target ₹2,000 · Active
- BUY Sapphire Foods India22 Oct 2026 · ~1 year · target ₹245 · Active
- BUY CIE Automotive India22 Oct 2026 · ~1 year · target ₹440 · Active
- BUY CREDITACCESS GRAMEEN22 Oct 2026 · ~1 year · target ₹1,450 · Active
- BUY KEI Industries22 Oct 2026 · ~1 year · target ₹5,180 · Active

